GI
HRMY icon

GAMCO Investors’s Harmony Biosciences HRMY Stock Holding History

GAMCO Investors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-9,800
Closed -$478K – 909
2022
Q2 		$478K Sell
9,800
-4,500
-31% -$203K 0.01% 702
2022
Q1 		$696K Buy
+14,300
New +$583K 0.01% 676

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

GAMCO Investors's HRMY Position: Q3 2022 in Review

GAMCO Investors sold out of Harmony Biosciences (HRMY) in Q3 2022, closing a stake of 9,800 shares — an estimated $478K sold.

GAMCO Investors first reported a position in HRMY in Q1 2022 and held it in 2 quarters. The position peaked at $696K in Q1 2022. 203 funds tracked by Wall St. Rank hold HRMY as of Q3 2022.

  • GAMCO Investors reported no remaining Harmony Biosciences position as of Q3 2022 after selling out during the quarter.
  • GAMCO Investors sold 9,800 Harmony Biosciences shares in Q3 2022, an estimated $478K.
  • GAMCO Investors first reported a position in Harmony Biosciences in Q1 2022 and held it in 2 quarters.
  • GAMCO Investors's Harmony Biosciences position peaked at $696K in Q1 2022.
  • 203 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2022.

Based on GAMCO Investors's 13F filing for Q3 2022, filed 10 Nov 2022.